AR016175A1 - Compuestos derivados del acido dihidroxihexanoico, su uso para la preparacion de medicamentos y composiciones de los mismos. - Google Patents

Compuestos derivados del acido dihidroxihexanoico, su uso para la preparacion de medicamentos y composiciones de los mismos.

Info

Publication number
AR016175A1
AR016175A1 ARP990100443A ARP990100443A AR016175A1 AR 016175 A1 AR016175 A1 AR 016175A1 AR P990100443 A ARP990100443 A AR P990100443A AR P990100443 A ARP990100443 A AR P990100443A AR 016175 A1 AR016175 A1 AR 016175A1
Authority
AR
Argentina
Prior art keywords
octyl
amide
methyl
carboxylic acid
dihydroxy
Prior art date
Application number
ARP990100443A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR016175A1 publication Critical patent/AR016175A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
ARP990100443A 1998-02-05 1999-02-03 Compuestos derivados del acido dihidroxihexanoico, su uso para la preparacion de medicamentos y composiciones de los mismos. AR016175A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7380198P 1998-02-05 1998-02-05

Publications (1)

Publication Number Publication Date
AR016175A1 true AR016175A1 (es) 2001-06-20

Family

ID=22115885

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100443A AR016175A1 (es) 1998-02-05 1999-02-03 Compuestos derivados del acido dihidroxihexanoico, su uso para la preparacion de medicamentos y composiciones de los mismos.

Country Status (36)

Country Link
EP (1) EP1051405B1 (enExample)
JP (1) JP3693916B2 (enExample)
KR (1) KR100385529B1 (enExample)
CN (1) CN1177834C (enExample)
AP (1) AP992A (enExample)
AR (1) AR016175A1 (enExample)
AT (1) ATE337307T1 (enExample)
AU (1) AU752407B2 (enExample)
BG (1) BG104726A (enExample)
BR (1) BR9907655A (enExample)
CA (1) CA2320388C (enExample)
DE (1) DE69932920T2 (enExample)
DZ (1) DZ2717A1 (enExample)
EA (1) EA003137B1 (enExample)
ES (1) ES2268847T3 (enExample)
GT (1) GT199900011A (enExample)
HR (1) HRP20000529B1 (enExample)
HU (1) HUP0100832A3 (enExample)
IL (1) IL137330A0 (enExample)
IS (1) IS5562A (enExample)
MA (1) MA26603A1 (enExample)
MY (1) MY133125A (enExample)
NO (1) NO20003965D0 (enExample)
NZ (1) NZ505724A (enExample)
OA (1) OA11448A (enExample)
PA (1) PA8467301A1 (enExample)
PE (1) PE20000243A1 (enExample)
PL (1) PL342817A1 (enExample)
SK (1) SK11262000A3 (enExample)
TN (1) TNSN99013A1 (enExample)
TR (1) TR200002248T2 (enExample)
TW (1) TW470744B (enExample)
UA (1) UA57824C2 (enExample)
WO (1) WO1999040061A2 (enExample)
YU (1) YU47100A (enExample)
ZA (1) ZA99873B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044365A1 (en) * 1999-01-29 2000-08-03 Millennium Pharmaceuticals, Inc. Methods for preventing graft rejection and ischemia-reperfusion injury
CA2376275A1 (en) * 1999-08-20 2001-03-01 Michael John Ricks Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
BR0108002A (pt) * 2000-02-04 2002-10-29 Pfizer Prod Inc Derivados de amidas heterocìclicas
EP1498417A1 (en) * 2000-02-04 2005-01-19 Pfizer Products Inc. Heterocyclic amide derivatives
US6740636B2 (en) * 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
US6746856B2 (en) 2000-08-09 2004-06-08 Pfizer Inc. Microbial conversion of bicyclic heteroaromatic compounds
KR100759635B1 (ko) 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
RU2004133530A (ru) * 2002-05-14 2005-06-10 Пфайзер Продактс Инк. (Us) Производные дигидроксигексановой кислоты, их промежуточные соединения и способы получения
BR0309932A (pt) * 2002-05-14 2005-02-09 Pfizer Prod Inc Métodos para a fabricação de derivados de diidro-furan-2-ona
CN1681479A (zh) 2002-08-12 2005-10-12 辉瑞产品公司 半有序药物和聚合物的药物组合物
CA2494776A1 (en) * 2002-08-12 2004-02-19 Pfizer Products Inc. Crystal forms of quinoxaline-2-carboxylic acid ¬4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl|-amide
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923864A (en) * 1987-12-15 1990-05-08 Pfizer Inc. Certain heterocyclic-hexanamides useful for treating hypertension
DE69527405T2 (de) * 1994-10-19 2003-03-13 Novartis Ag, Basel Antivirale Ether von Aspartat-Protease-Substrat-Isosteren
DE19708106A1 (de) * 1997-02-28 1998-09-03 Bosch Gmbh Robert Einrichtung und Verfahren zur Information über Verkehrsstörungen

Also Published As

Publication number Publication date
DE69932920T2 (de) 2007-02-08
YU47100A (sh) 2002-11-15
HRP20000529A2 (en) 2001-08-31
WO1999040061A3 (en) 1999-10-21
HUP0100832A3 (en) 2002-03-28
NZ505724A (en) 2003-02-28
BG104726A (en) 2001-04-30
TW470744B (en) 2002-01-01
NO20003965L (enExample) 2000-10-03
TR200002248T2 (tr) 2000-12-21
EP1051405A2 (en) 2000-11-15
DE69932920D1 (de) 2006-10-05
KR20010040684A (ko) 2001-05-15
EP1051405B1 (en) 2006-08-23
AP992A (en) 2001-08-06
IS5562A (is) 2000-07-14
DZ2717A1 (fr) 2003-09-01
HUP0100832A2 (hu) 2002-02-28
ES2268847T3 (es) 2007-03-16
CA2320388A1 (en) 1999-08-12
NO20003965D0 (no) 2000-08-04
HK1034969A1 (en) 2001-11-09
EA003137B1 (ru) 2003-02-27
JP3693916B2 (ja) 2005-09-14
GT199900011A (es) 2000-07-20
PL342817A1 (en) 2001-07-02
HRP20000529B1 (en) 2004-12-31
WO1999040061A2 (en) 1999-08-12
UA57824C2 (uk) 2003-07-15
ATE337307T1 (de) 2006-09-15
CN1177834C (zh) 2004-12-01
MY133125A (en) 2007-10-31
PE20000243A1 (es) 2000-04-07
AP9901457A0 (en) 1999-03-31
AU752407B2 (en) 2002-09-19
SK11262000A3 (sk) 2001-01-18
BR9907655A (pt) 2000-10-24
ZA99873B (en) 2000-08-04
CN1290255A (zh) 2001-04-04
TNSN99013A1 (fr) 2005-11-10
EA200000741A1 (ru) 2001-02-26
PA8467301A1 (es) 2000-05-24
MA26603A1 (fr) 2004-12-20
JP2002502839A (ja) 2002-01-29
AU1778999A (en) 1999-08-23
CA2320388C (en) 2005-05-03
IL137330A0 (en) 2001-07-24
OA11448A (en) 2003-11-18
KR100385529B1 (ko) 2003-05-27

Similar Documents

Publication Publication Date Title
EE9900217A (et) Sulfiinhappe derivaadid, nende valmistamine ja kasutamine
BR0307599A (pt) Derivados de sulfonilamino como inibidores de histona deacetilase
ES2067813T3 (es) Derivados substituidos de valinamida.
BG101422A (bg) Бензоксазолни производни като бронхоразширяващи средства
UY27892A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos.
BR0115580A (pt) Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2
AR036331A1 (es) Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
BR0112786A (pt) Inibidores de inflamação não-esteroidais
BRPI0315143B8 (pt) composto, composição farmacêutica, e, uso de um composto
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
RU94023250A (ru) 2,3-дигидро-1,4-бензодиоксин-5-ил-пиперазиновые производные, обладающие 5-нт1а-антагонистической активностью, способы их получения, фармкомпозиция на их основе, получение ее и способ лечения расстройств нервной системы
MX9304399A (es) Proceso novedoso para preparar [[2-bromoetil)-amino]metil]-2-nitro-1h-imidazol-1-etanol quiral y compuestos relacionados.
GT199900011A (es) Nuevos derivados del acido dihidroxihexanoico
BR0212716A (pt) Inibidores de liberação extracelular de citocinas inflamatórias e composição farmacêutica
AR029461A1 (es) Derivados de 4-fenil-1-piperazinilo, - piperidinilo y -tetrahidropiridilo , composiciones farmaceuticas que los comprenden y el uso de los mismos para la fabricacion de un medicamento
ES2155621T3 (es) Derivados azo del acido 5-aminosalicilico para el tratamiento de la enfermedad inflamatoria intestinal.
ES2068497T3 (es) Derivados de urea, su produccion, y composiciones farmaceuticas que los contienen.
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.
ES2056639T3 (es) Procedimiento para la transformacion del acido (benzoil-3 fenil)-2 propionico-r(-) en isomero s(+).
DE69927813D1 (de) Hyperforin-derivate, ihre verwendung sowie diese enthaltende zubereitungen
PT1430047E (pt) Derivados de alquilaminopiridazinona substituida, processo para a sua preparacao e composicoes farmaceuticas que os contem
BR0110490B1 (pt) agentes de tingimento contendo derivados de n-heteroarilmetil-m-fenilenodiamina para fibras de queratina bem como novos derivados de n-heteroarilmetil-m-fenilenodiamina.
MX9405111A (es) Nuevos derivados de (1-fenil-1-heterociclil)metanol y(1-fenil-1-heterociclil-metilamina).
DK0745081T3 (da) Indan-2-mercaptoacetylamiddisulfidderivater, der er anvendelige som enkephalinase-inhibitorer
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri

Legal Events

Date Code Title Description
FB Suspension of granting procedure